SCHEMBL17536981

SCHEMBL17536981

CC(C)(C)OC(=O)N1CCN(c2ccc(Nc3ncc4c(=O)n(-c5c(Cl)cccc5Cl)ccc4n3)cc2CO)CC1

nearest known ligand 0.62

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 18/20 0.62
KCNH2 Q12809 6/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17536949 0.93 WEE1 (0.67) WEE1KCNH2
SCHEMBL17536951 0.91 KCNH2 (0.73) WEE1KCNH2
SCHEMBL17536970 0.91 WEE1 (0.65) WEE1KCNH2
SCHEMBL17536952 0.90 WEE1 (0.64) WEE1KCNH2
SCHEMBL17536965 0.89 WEE1 (0.78) WEE1KCNH2
SCHEMBL16176041 0.88 WEE1 (0.76) WEE1KCNH2
SCHEMBL17536947 0.88 WEE1 (0.79) WEE1KCNH2
SCHEMBL17536986 0.85 WEE1 (0.70) WEE1KCNH2
SCHEMBL16176030 0.85 KCNH2 (0.78) WEE1KCNH2
SCHEMBL17536998 0.83 KCNH2 (0.62) WEE1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714244-B2 Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors ALMAC DISCOVERY LIMITED (GB) 2017-07-25 US disclosed
EP-2984090-B1 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS ALMAC DISCOVERY LTD (GB) 2017-05-31 EP disclosed
US-20160060258-A1 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2016-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060258-A1 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS WEE1, WEE2, NME1 WEE1 1/4885KCNH2 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.